Transforming clinical decisions. Getting antibiotics right.

Abtrace develops an algorithm to better understand clinical decisions on antibiotics prescriptions and provides clinicians with the information that will aid a better choice.

About Our Project

Antimicrobial Resistance (AMR) is a growing concern, resulting in an estimated 10 million deaths worldwide by 2050 – more than cancer and diabetes combined.

Every use of an antibiotic comes with a risk that resistance might develop. However, between 20-50% of antibiotics prescribed are unnecessary or inappropriate and this has a clear impact on the health outcomes and costs in care for both the individual and society.

The correct choice of antibiotic gives a triple benefit: better treatment for the patient, less money spent on consuming the wrong antibiotics, and ultimately the reduction of AMR by selecting the right drug for the right bug.

Abtrace uses artificial intelligence techniques to better understand clinical decisions and provide the clinician with the information that will aid a better choice, instantly, for every patient and every prescription.

Abtrace is based at the Insituto Pedro Nunes in Coimbra – Portugal.

You can find out more on our website.

Meet the Team

Dr Umar Naeem Ahmad

Umar Naeem Ahmad is a clinician with experience in Infectious Disease, Intensive Care and Emergency Medicine, based in the UK. He has worked on projects in 9 countries, ranging from the WHO in Switzerland to the Ebola response in Sierra Leone. He has been managing healthcare workers and transforming clinical pathways to improve quality of care through digital solutions.

Dr Cristina Correia

Cristina Correia brings strong experience in medical device product development, business development and regulatory affairs, having managed R&D teams and funds towards consistent generation of scientific publications and intellectual property. She is a graduate of Biomedical Engineering and is based in Portugal.

Helder Soares

Helder Soares is trained in Medicinal Chemistry, also based in Portugal. Helder is skilled in effectively leading research teams both in academia and in the pharmaceutical industry holding intellectual property on novel solutions for antimicrobial resistance.

Our JOURNEY SINCE WILD CARD

  • Developing core, state-of-the-art technology and algorithms – the basis of our solution.
  • Planning to pilot our algorithm across a number of sites including Barts Health NHS Trust, and Imperial College NHS Trust.
  • National level pilot programmes being planned with Health Data Research UK and NHS Digital.

Our Wild Card Experience

Wild Card has been a rollercoaster of challenges and emotions, and a unique learning experience. EIT Health set up this programme designed to support game changing ideas in the healthcare field and in the next few months we hope to be walking that path towards revolutionising the way antibiotics are prescribed.

The Abtrace approach can and is urgently needed to fight back against the rising threat of AMR.